8/9/2010

The FDA issued a warning letter to Dendreon, saying some promotional materials for Provenge, a vaccine for prostate cancer, exaggerated benefits and minimized risks. Dendreon "intends to comply" with the FDA's request to stop using those materials, a spokeswoman said.

Full Story:
Reuters

Related Summaries